PrognoScan: a new database for meta-analysis of the prognostic value of genes

被引:803
作者
Mizuno, Hideaki [1 ,3 ]
Kitada, Kunio [1 ]
Nakai, Kenta [2 ]
Sarai, Akinori [3 ]
机构
[1] Chugai Pharmaceut Co Ltd, Kamakura Res Labs, Dept Pharmaceut Technol, Kanagawa, Japan
[2] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo, Japan
[3] Kyushu Inst Technol, Dept Biosci & Bioinformat, Fukuoka, Japan
来源
BMC MEDICAL GENOMICS | 2009年 / 2卷
关键词
BREAST-CANCER PATIENTS; ACUTE MYELOID-LEUKEMIA; EXPRESSION PROFILES; PREDICTING PROGNOSIS; SIX1; OVEREXPRESSION; OPTIMAL CUTPOINTS; HISTOLOGIC GRADE; SQUAMOUS-CELL; KAPPA-B; SURVIVAL;
D O I
10.1186/1755-8794-2-18
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: In cancer research, the association between a gene and clinical outcome suggests the underlying etiology of the disease and consequently can motivate further studies. The recent availability of published cancer microarray datasets with clinical annotation provides the opportunity for linking gene expression to prognosis. However, the data are not easy to access and analyze without an effective analysis platform. Description: To take advantage of public resources in full, a database named "PrognoScan" has been developed. This is 1) a large collection of publicly available cancer microarray datasets with clinical annotation, as well as 2) a tool for assessing the biological relationship between gene expression and prognosis. PrognoScan employs the minimum P-value approach for grouping patients for survival analysis that finds the optimal cutpoint in continuous gene expression measurement without prior biological knowledge or assumption and, as a result, enables systematic meta-analysis of multiple datasets. Conclusion: PrognoScan provides a powerful platform for evaluating potential tumor markers and therapeutic targets and would accelerate cancer research. The database is publicly accessible at http://gibk21.bse.kyutech.ac.jp/PrognoScan/index.html.
引用
收藏
页数:11
相关论文
共 62 条
[1]  
ABEL U, 1984, METHOD INFORM MED, V23, P154
[2]   Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer [J].
Als, Anne B. ;
Dyrskjot, Lars ;
von der Maase, Hans ;
Koed, Karen ;
Mansilla, Francisco ;
Toldbod, Helle E. ;
Jensen, Jens L. ;
Ulhoi, Benedicte P. ;
Sengelov, Lisa ;
Jensen, Klaus M. E. ;
Orntoft, Torben F. .
CLINICAL CANCER RESEARCH, 2007, 13 (15) :4407-4414
[3]   DANGERS OF USING OPTIMAL CUTPOINTS IN THE EVALUATION OF PROGNOSTIC FACTORS [J].
ALTMAN, DG ;
LAUSEN, B ;
SAUERBREI, W ;
SCHUMACHER, M .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (11) :829-835
[4]   Age-Specific Differences in Oncogenic Pathway Deregulation Seen in Human Breast Tumors [J].
Anders, Carey K. ;
Acharya, Chaitanya R. ;
Hsu, David S. ;
Broadwater, Gloria ;
Garman, Katherine ;
Foekens, John A. ;
Zhang, Yi ;
Wang, Yixin ;
Marcom, Kelly ;
Marks, Jeffrey R. ;
Mukherjee, Sayan ;
Nevins, Joseph R. ;
Blackwell, Kimberly L. ;
Potti, Anil .
PLOS ONE, 2008, 3 (01)
[5]   NCBI GEO: mining tens of millions of expression profiles - database and tools update [J].
Barrett, Tanya ;
Troup, Dennis B. ;
Wilhite, Stephen E. ;
Ledoux, Pierre ;
Rudnev, Dmitry ;
Evangelista, Carlos ;
Kim, Irene F. ;
Soboleva, Alexandra ;
Tomashevsky, Maxim ;
Edgar, Ron .
NUCLEIC ACIDS RESEARCH, 2007, 35 :D760-D765
[6]   Gene-expression profiles predict survival of patients with lung adenocarcinoma [J].
Beer, DG ;
Kardia, SLR ;
Huang, CC ;
Giordano, TJ ;
Levin, AM ;
Misek, DE ;
Lin, L ;
Chen, GA ;
Gharib, TG ;
Thomas, DG ;
Lizyness, ML ;
Kuick, R ;
Hayasaka, S ;
Taylor, JMG ;
Iannettoni, MD ;
Orringer, MB ;
Hanash, S .
NATURE MEDICINE, 2002, 8 (08) :816-824
[7]   Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival [J].
Behbakht, Kian ;
Qamar, Lubna ;
Aldridge, Carrie S. ;
Coletta, Ricardo D. ;
Davidson, Susan A. ;
Thorburn, Andrew ;
Ford, Heide L. .
CANCER RESEARCH, 2007, 67 (07) :3036-3042
[8]   Oncogenic pathway signatures in human cancers as a guide to targeted therapies [J].
Bild, AH ;
Yao, G ;
Chang, JT ;
Wang, QL ;
Potti, A ;
Chasse, D ;
Joshi, MB ;
Harpole, D ;
Lancaster, JM ;
Berchuck, A ;
Olson, JA ;
Marks, JR ;
Dressman, HK ;
West, M ;
Nevins, JR .
NATURE, 2006, 439 (7074) :353-357
[9]   Multimodality therapy for pancreatic cancer in the US - Utilization, outcomes, and the effect of hospital volume [J].
Bilimoria, Karl Y. ;
Bentrem, David J. ;
Ko, Clifford Y. ;
Tomlinson, James S. ;
Stewart, Andrew K. ;
Winchester, David P. ;
Talamonti, Mark S. .
CANCER, 2007, 110 (06) :1227-1234
[10]   Ki67 protein: the immaculate deception? [J].
Brown, DC ;
Gatter, KC .
HISTOPATHOLOGY, 2002, 40 (01) :2-11